- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
552
Performance of Serum Hbcrag in Chronic
Hepatitis B Patients with 8-Year Nucleos(t)Ide
Analogs Therapy
Meng-Lan Wang1, Enqiang Chen1, Juan Liao1, Juan Wang1
and Hong Tang2, (1)Center of Infectious Diseases, West
China Hospital of Sichuan University, (2)West China Hospital
of Sichuan University
Background: This study aimed to investigate long-term
kinetics of serum hepatitis B core-related antigen (HBcrAg) and
its correlation with serum hepatitis B surface antigen(HBsAg)
in a real-world cohort of patients who had received over 8
years of nucleos(t)ide analogs(NAs) therapy. Methods: This
was a retrospective study. All patients were recruited from
our previous published study, who started therapy with NAs
between 2007 and 2008. Serum HBcrAg and HBsAg levels
were quantitatively measured at baseline, the sixth month
and each year of follow-up, using the stored serum samples.
Results: Among the 94 patients, serum HBcrAg presented
a gradually decreasing trend from baseline to year 8, either
in HBeAg-negative or HBeAg-positive patients(Figure).
After 8 years of NAs treatment, 21.3% of patients achieved
serum HBcrAg<3 log 10 U/mL, and only baseline HBcrAg
was an independent predictor. Additionally, good correlation
of HBcrAg and HBsAg was observed at baseline, but
this correlation weakened remarkably during treatment.
Conclusion: Serum HBcrAg is decreasing gradually with the
duration of antiviral therapy, and baseline HBcrAg level is an
independent predictor of long-term HBcrAg below the limit of
detection.
|
|